Home → Focus

Feds greenlight healthcare mega merger Print E-mail
Written by CNN   
Wednesday, 10 October 2018 00:00
David Goldman reports for CNN Business on 10.10.18:
A landmark healthcare merger is inches away from the finish line. CVS has gained the US government's approval to buy Aetna. The $69 billion acquisition, announced in December 2017, will drastically remap  the healthcare industry. CVS is a massive drugstore chain and prescription insurer, and Aetna is one of the nation's largest health insurers. It is the largest health insurance deal in history, far exceeding Express Scripts' $29 billion acquisition of Medco in 2012, the last record-holder. To gain the Trump administration's approval, Aetna agreed to spin off its Medicare Part D prescription drug business. The Justice Department settled with CVS and Aetna on Wednesday. Pending a judge's approval of the settlement, the deal will be completed.

Last Updated on Friday, 12 October 2018 11:28
Physicians' regulatory burden worse than ever despite federal efforts Print E-mail
Written by FHI's Week in Review   
Monday, 08 October 2018 13:19
Virgil Dickson reports for Modern Healthcare on 10.4.18:

The CMS has prided itself in recent months on cutting and scaling back providers' regulatory burden, but those efforts have fallen short, according to a new survey by the Medical Group Management Association. An overwhelming majority, or 86%, of respondents reported the overall regulatory burden on their medical practice has increased over the past 12 months.

Read more in the current issue of Week in Review>>
Last Updated on Monday, 19 November 2018 18:03
DEA Reschedules Epidiolex, Paving the Way to Market Print E-mail
Written by FHI's Week in Review   
Monday, 01 October 2018 00:00
Megan Brooks reports for Medscape on 9.27.18:
The U.S. Drug Enforcement Administration (DEA) has rescheduled the epilepsy cannabidiol (CBD) drug Epidiolex (GW Pharmaceuticals) from Schedule I to Schedule V, the classification with the lowest degree of restriction - paving the way to market for the cannabis-based treatment, the company has announced. As reported by Medscape Medical News, the U.S. Food and Drug Administration (FDA) approved the drug in June for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients aged 2 years and older. The approval followed a unanimous thumbs up by an FDA advisory committee in April.
Read more in the current issue of Week in Review>>
Last Updated on Monday, 01 October 2018 17:50
These Are the Economies With the Most (and Least) Efficient Health Care Print E-mail
Written by FHI's Week in Review   
Monday, 24 September 2018 17:36
Bloomberg published its annual global health analysis on September 19. As usual, it's depressing news for Americans. According to authors Lee J. Miller and Wei Lui:

The U.S. will cost you the most for treatment, both in absolute terms and relative to average incomes, while life expectancy of Americans -- about 79 years -- was exceeded by more than 25 countries and territories, according to an annual Bloomberg analysis in almost 200 economies.
Read more in the current issue of Week in Review>>
Last Updated on Friday, 26 October 2018 11:37
Opioid Crackdown Nets South Florida Doctor as Efforts Intensify Print E-mail
Written by Vitale Health Law   
Tuesday, 18 September 2018 17:27
A South Florida doctor is the latest to be sentenced for his role in the illegal distribution of opioids. Earlier this month, Dr. Andres Mencia of Fort Lauderdale was sentenced to more than six years in prison, after being convicted by a federal jury of taking part in a conspiracy to distribute a controlled substance.
Mencia's arrest and conviction are part of a large scale war on illegal opioid trafficking. In April, the Drug Enforcement Administration (DEA) announced it had reached a prescription drug information-sharing agreement with 48 Attorneys General to share prescription drug information with one another to aid investigations. According to evidence presented during his trial, Dr. Mencia ran Adult & Geriatric Institute of Fort Lauderdale where, between January 2014 and October 2017, he and others in his office performed "sham" consultations with cash-paying patients. These "consultations," according to evidence presented during the trial, were for the intended purpose of improperly issuing prescriptions for opioids and other narcotics, including Oxycodone, OxyContin and Percocet, in exchange for cash.

Read More
Last Updated on Tuesday, 18 September 2018 17:31
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 3 of 129

Website design, development, and hosting provided by